Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH. Proctor SJ, et al. Among authors: angus b. Eur J Haematol Suppl. 2001 Jul;64:28-32. Eur J Haematol Suppl. 2001. PMID: 11486397 Clinical Trial.
Hodgkin's disease in the elderly: a population-based study.
Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR; Northern Region Lymphoma Group. Stark GL, et al. Among authors: angus b. Br J Haematol. 2002 Nov;119(2):432-40. doi: 10.1046/j.1365-2141.2002.03815.x. Br J Haematol. 2002. PMID: 12406082 Free article.
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
Jackson GH, Angus B, Carey PJ, Finney RD, Galloway MJ, Goff DK, Haynes A, Lennard AL, Leonard RC, McQuaker IG, Proctor SJ, Russell N, Windebank K, Taylor PR; Scotland and Newcastle Lymphoma Group. Jackson GH, et al. Among authors: angus b. Leuk Lymphoma. 2000 May;37(5-6):561-70. doi: 10.3109/10428190009058508. Leuk Lymphoma. 2000. PMID: 11042516 Clinical Trial.
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).
Proctor SJ, Mackie M, Dawson A, White J, Prescott RJ, Lucraft HL, Angus B, Jackson GH, Lennard AL, Hepplestone A, Taylor PR. Proctor SJ, et al. Among authors: angus b. Eur J Cancer. 2002 Apr;38(6):795-806. doi: 10.1016/s0959-8049(02)00006-0. Eur J Cancer. 2002. PMID: 11937314 Clinical Trial.
Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).
Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, White J, Windebank K, Taylor PR; Northern Region Lymphoma Group. Proctor SJ, et al. Among authors: angus b. Ann Oncol. 2003;14 Suppl 1:i47-50. doi: 10.1093/annonc/mdg710. Ann Oncol. 2003. PMID: 12736232 Free article.
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group.
Cameron DA, White JM, Proctor SJ, Prescott RJ, Leonard RC, Angus B, Cook MK, Dawes PJ, Dawson AA, Evans RG, Galloway MJ, Harris AL, Heppleston A, Horne CH, Krajewski AS, Lennard AL, Lessells AM, Lucraft HH, MacGillivray JB, Mackie MJ, Parker AC, Roberts JT, Taylor PR, Thompson WD. Cameron DA, et al. Among authors: angus b. Eur J Cancer. 1997 Jul;33(8):1195-201. doi: 10.1016/s0959-8049(97)00051-8. Eur J Cancer. 1997. PMID: 9301442 Clinical Trial.
Hodgkin's disease in the elderly: current status and future directions.
Proctor SJ, Rueffer JU, Angus B, Breuer K, Flechtner H, Jarrett R, Levis A, Taylor P, Tirelli U. Proctor SJ, et al. Among authors: angus b. Ann Oncol. 2002;13 Suppl 1:133-7. doi: 10.1093/annonc/13.s1.133. Ann Oncol. 2002. PMID: 12078895 Free article.
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, Lessells AM, Lucraft HH, Summerfield GP, Proctor SJ; Scotland And Newcastle Lymphoma Group. Taylor PR, et al. Among authors: angus b. Leuk Lymphoma. 2006 Nov;47(11):2321-30. doi: 10.1080/10428190600881256. Leuk Lymphoma. 2006. PMID: 17107904 Clinical Trial.
336 results